Related Experiment Video

Updated: Aug 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?

Keiichi Fujiwara1, Katsuyuki Kiura, Kenichi Gemba

  • 1Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.

Anticancer Research
|April 9, 2005
PubMed

Insights

Gefitinib shows promise in non-small cell lung cancer (NSCLC). Retreatment with cytotoxic agents may restore sensitivity in patients refractory to gefitinib, offering new hope for advanced NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gefitinib (Iressa, ZD1839) demonstrates antitumor activity in non-small cell lung cancer (NSCLC).
  • Limited treatment options exist for advanced NSCLC patients refractory to gefitinib.
  • Chemosensitivity loss is a challenge in NSCLC treatment.

Purpose of the Study:

  • To investigate the efficacy of retreatment with cytotoxic agents in advanced NSCLC patients previously responsive to gefitinib.
  • To explore the potential of gefitinib to restore chemosensitivity in refractory NSCLC.
  • To present case studies of gefitinib-refractory NSCLC patients treated with cytotoxic agents.

Main Methods:

  • Case series of four patients with advanced NSCLC.
  • Patients had previously responded to gefitinib treatment.
  • Retreatment involved various cytotoxic agents.

Main Results:

  • All four patients achieved significant tumor regression upon retreatment with cytotoxic agents.
  • The study observed a restoration of chemosensitivity in previously refractory patients.
  • Individual patient responses varied but were notably positive.

Conclusions:

  • Retreatment with cytotoxic agents can be effective in advanced NSCLC patients refractory to gefitinib.
  • Gefitinib may play a role in restoring chemosensitivity, enabling subsequent treatment success.
  • These findings suggest a potential strategy for managing gefitinib-refractory NSCLC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...